Source: Annual Congress 2007 - New insights into the treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. K. Bhattacharya, S. Bhargav, V. Singh, D. Talwar, J. Whig, S. Naik, C. J. Po, S. M. Purandare, A. Sule, J. A. Gogtay (Ahmedabad, Indore, Jaipur, Noida, Ludhiana, Mumbai, India). Non-inferiority comparison of ipratropium-salbutamol HFA (IB/SAL-HFA) pMDI with ipratropium salbutamol CFC (IF/SAL-CFC) pMDI in patients with COPD. Eur Respir J 2007; 30: Suppl. 51, 3593

Member's Comments

No comment yet.

Related content which might interest you: Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007 Non-inferiority comparison of budesonide HFA (BUD-HFA) pMDI with budesonide CFC (BUD-CFC) pMDI in patients with persistent moderate asthma Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 Non inferiority comparison of salmeterol HFA (SM-HFA) pMDI with salmeterol CFC (SM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007 Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004 Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003 The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001 Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Comparison of HFA fluticasone-formoterol combination pressurized meter dose inhaler (pMDI) and HFA budesonide-formoterol combination pMDI in patients with moderate to severe persistent asthma Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010 Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 100s Year: 2007 Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Formoterol via turbuhaler (F) versus salbutamol via pressurized metered-dose inhaler (SB) in acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 425s Year: 2001 Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005 Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003 QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009 Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI) Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009 Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 206s Year: 2006 Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020